X
API Suppliers
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
Details:
ALX Oncology will use the proceeds to fund ongoing development of ALX148 (evorpacept), a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain, for hematologic and solid malignancies.
Lead Product(s): Evorpacept,Trastuzumab,Ramucirumab
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Piper Sandler
Deal Size: $63.2 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 10, 2023
Details:
ALX Oncology will use the proceeds to fund ongoing development of ALX148 (evorpacept), a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain, for hematologic and solid malignancies.
Lead Product(s): Evorpacept,Trastuzumab,Ramucirumab
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Piper Sandler
Deal Size: $55.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering October 05, 2023
Details:
ALX Oncology will use the proceeds to fund ongoing development of ALX148 (evorpacept), a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain with an inactivated, proprietary Fc domain, for hematologic and solid malignancies.
Lead Product(s): Evorpacept,Trastuzumab,Ramucirumab
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Piper Sandler
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Public Offering October 04, 2023
Details:
ALX148 (evorpacept) is a next generation CD47 blocker, which is being investigated in combination with trastuzumab in patients with HER2-positive gastric/gastroesophageal junction (“GEJ”) cancer.
Lead Product(s): Evorpacept,Trastuzumab,Ramucirumab
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 03, 2023
Details:
ALX148 (evorpacept) is a next generation CD47 blocker, which is being investigated in patients with gastric cancer and gastroesophageal junction adenocarcinoma.
Lead Product(s): Evorpacept,Trastuzumab,Ramucirumab
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 26, 2023
Details:
CYRAMZA (ramucirumab), an antiangiogenic therapy and VEGF Receptor 2 antagonist, demonstrated and was well-tolerated in Chinese patients and overall patient population, safety and efficacy profile in Chinese population was consistent with global studies.
Lead Product(s): Ramucirumab
Therapeutic Area: Oncology Product Name: Cyramza
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 10, 2022
Details:
Under the terms of the agreement, upon regulatory approvals of Cyramza® in the hepatocellular carcinoma indication and Retsevmo® in the non-small lung cancer indication, and then intends to commercialize Cyramza® and Retsevmo® in China.
Lead Product(s): Ramucirumab
Therapeutic Area: Oncology Product Name: Cyramza
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Innovent Biologics
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Partnership March 28, 2022
Details:
Evorpacept used in combination with ramucirumab, trastuzumab, and paclitaxel demonstrated an initial confirmed objective response rate of 72.2% with a median duration of response of 14.8 months, a 12-month overall survival rate of 79%.
Lead Product(s): Evorpacept,Trastuzumab,Ramucirumab
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 02, 2022
Details:
ALX148, is a next generation CD47 blocking therapeutic that combines a high-affinity CD47 binding domain. ALX148 has demonstrated promising clinical responses across a range of hematologic and solid malignancies in combination with a number of leading anti-cancer agents.
Lead Product(s): Evorpacept,Trastuzumab,Ramucirumab
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 27, 2022
Details:
The synergistic effect between derazantinib and paclitaxel is particularly encouraging as we are exploring derazantinib alone and in combination settings, including paclitaxel, in our clinical phase 1/2 study FIDES-03 in patients with gastric cancer.
Lead Product(s): Derazantinib,Paclitaxel,Ramucirumab
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 11, 2021
Details:
ALX Oncology will conduct a randomized Phase 2/3 study to evaluate the efficacy of ALX148 in combination with ramucirumab, trastuzumab, and paclitaxel for the treatment of patients whose tumors have progressed following treatment with HER2-targeted therapy and chemotherapy.
Lead Product(s): ALX148,Ramucirumab,Trastuzumab
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: ALX Oncology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 10, 2021
Details:
Updated results will be presented from ASPEN-01, the ongoing Phase 1b Study of ALX148 in combination trastuzumab, ramucirumab and paclitaxel in patients with gastric or gastroesophageal junction cancer.
Lead Product(s): ALX148,Trastuzumab,Ramucirumab
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 21, 2021
Details:
In patients with >2L HER2 positive GC, whose tumors have progressed upon prior trastuzumab therapy, ALX148 shows a promising initial objective response rate of 64% in combination with trastuzumab plus ramucirumab and paclitaxel that compares favorably with historical data.
Lead Product(s): ALX148,Trastuzumab,Ramucirumab
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
The FIDES-03 study will assess the efficacy and safety of derazantinib as monotherapy and combination therapy with ramucirumab and paclitaxel or with Roche’s PD-L1 checkpoint inhibitor atezolizumab.
Lead Product(s): Ramucirumab,Derazantinib,Paclitaxel
Therapeutic Area: Oncology Product Name: Cyramza
Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Basilea Pharmaceutica
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 28, 2020
Details:
The presented data from several preclinical models demonstrate that derazantinib has an anti-angiogenic effect, which may contribute to its overall anti-tumor activity in FGFR-driven cancers.
Lead Product(s): Derazantinib,Ramucirumab,Paclitaxel
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 26, 2020
Details:
Poster titled "ALX148, a CD47 blocker, in combination with standard chemotherapy and antibody regimens in patients with gastric/gastroesophageal junction cancer and head and neck squamous cell carcinoma will be presented at the conference.
Lead Product(s): ALX148,Trastuzumab,Ramucirumab
Therapeutic Area: Oncology Product Name: ALX148
Highest Development Status: Phase IProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2020
Details:
Lilly to supply Pieris with ramucirumab for the study as well as collaborate on data from the trial. Pieris is working towards initiation of a phase 2 single-arm combination study for the second-line treatment of HER2-positive gastric cancer later this year.
Lead Product(s): PRS-343,Ramucirumab,Paclitaxel
Therapeutic Area: Oncology Product Name: PRS-343
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 10, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
